Case 4
A 15-year-old girl with neurofibromatosis type I received imatinib, STR, and trametinib to manage a multiply-progressive plexiform neurofibroma (PN).
After 26 months of trametinib with continued gradual PD, lenalidomide was added to her therapy. She experienced SD for 12 months with no attributable adverse effects. The combination was held in preparation for resection of her PN. Given the safety concerns following the thromboembolic events described above, the decision was made to restart lenalidomide only.